BOTHELL, Wash., Oct. 21, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (“BioLife” or the “Company”), announced today that Frederick, MD based RoosterBio, Inc., has adopted the Company’s CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio’s human bone marrow-derived, adult mesenchymal stem cell (hMSC) products. RoosterBio’s hMSC products are being used by researchers throughout the world to accelerate the development of cellular therapies and engineered tissues targeting major diseases and disorders affecting millions of patients each year.
Jon Rowley, PhD., President & CEO of RoosterBio, commented on the decision to commercialize Rooster’s cryopreserved hMSC products with CryoStor by stating, “Our team has a long history of observing improved post-preservation cell survival and functional recovery enabled by the use of CryoStor, a clinical grade freeze media engineered to better protect cells from preservation-induced injury and death. Our customers are benefitting from increased quantity and quality of cells following cryopreservation, with rapid recovery and regrowth saving precious time and money in their development programs.”
Mike Rice, BioLife President & CEO, stated, “We are very pleased that RoosterBio has chosen CryoStor as the cryopreservation media for its high volume adult hMSC products. A growing number of cell suppliers are realizing the benefits CryoStor enables in improved yield and quality of cryopreserved cells and cell lines. End users conducting research on potential clinical applications of mesenchymal stem cells will continually seek to source very high quality cells from suppliers like RoosterBio. It is very satisfying to see the biopreservation efficacy and quality footprint of CryoStor being recognized by RoosterBio, an emerging and very promising supplier of clinically relevant cells.”
About RoosterBio
RoosterBio is a privately held biofabrication tools company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, where researchers spend newly found time & money performing more high-value experiments, accelerating the road to discovery in Regenerative Medicine. For more information, you can visit www.roosterbio.com, follow them on twitter (@RoosterBio), or read their highly-regarded blog Democratizing Cell Technologies (http://www.roosterbio.blogspot.com).
About BioLife Solutions
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This press release contains forward-looking statements, including, but not limited to, statements concerning the company’s anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM’s products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations
Daphne Taylor
Senior Vice President, Chief Financial Officer
(425) 402-1400
dtaylor@biolifesolutions.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roosterbio-selects-biolife-solutions-cryostor-to-commercialize-human-bone-marrow-derived-stem-cells-237041886.html
SOURCE BioLife Solutions, Inc.
Help employers find you! Check out all the jobs and post your resume.
